Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>IDEXX Laboratories, a prominent player in the diagnostics and veterinary healthcare sector, demonstrated a mixed performance in its latest earnings report for the third quarter of 2024.</li><li>The financial outcomes and the company's strategic movements indicate both strengths and challenges that prospective investors should consider.</li><li>Starting with the positives, IDEXX reported a 6% organic revenue growth, driven significantly by a 7% increase in Companion Animal Group (CAG) Diagnostic recurring revenues and a robust 13% growth in the water business.</li></ul>

IDEXX Laboratories, a prominent player in the diagnostics and veterinary healthcare sector, demonstrated a mixed performance in its latest earnings report for the third quarter of 2024.The financial outcomes and the company's strategic movements indicate both strengths and challenges that prospective investors should consider.Starting with the positives, IDEXX reported a 6% organic revenue growth, driven significantly by a 7% increase in Companion Animal Group (CAG) Diagnostic recurring revenues and a robust 13% growth in the water business.

IDEXX Labs: Will Its Enhanced Diagnostic Capabilities & Innovation Bring A Shift In The Competitive Dynamics? - Major Drivers

<ul><li>IDEXX Laboratories recently reported its financial results for the second quarter of 2024.</li><li>The company saw organic revenue growth of 7%, driven by a 7% increase in Companion Animal Group (CAG) Diagnostic recurring revenues and a 10% growth in its water business.</li><li>Despite facing macroeconomic and sector-specific challenges, including a 2% decline in U.S. same-store clinical visit growth, IDEXX demonstrated resilience by leveraging solid execution strategies such as high premium instrument placements and gains in veterinary software and diagnostic imaging revenues.</li></ul>

IDEXX Laboratories recently reported its financial results for the second quarter of 2024.The company saw organic revenue growth of 7%, driven by a 7% increase in Companion Animal Group (CAG) Diagnostic recurring revenues and a 10% growth in its water business.Despite facing macroeconomic and sector-specific challenges, including a 2% decline in U.S. same-store clinical visit growth, IDEXX demonstrated resilience by leveraging solid execution strategies such as high premium instrument placements and gains in veterinary software and diagnostic imaging revenues.

IDEXX Laboratories Inc.: Expanding Diagnostic Offerings & Executing Global Expansion & Strategic Acquisitions! - Major Drivers

<ul><li>IDEXX Laboratories began 2024 on a positive note, highlighted by strong profit gains and solid organic revenue growth.</li><li>In the first quarter, the company's overall revenues increased by 7%, organically, underpinned by 7% organic growth in Companion Animal Group (CAG) Diagnostic recurring revenues.</li><li>This robust growth occurred despite adverse effects from severe U.S. weather in January that the company estimates lowered overall organic revenue growth by 0.5% to 1%.</li></ul>

IDEXX Laboratories began 2024 on a positive note, highlighted by strong profit gains and solid organic revenue growth.In the first quarter, the company's overall revenues increased by 7%, organically, underpinned by 7% organic growth in Companion Animal Group (CAG) Diagnostic recurring revenues.This robust growth occurred despite adverse effects from severe U.S. weather in January that the company estimates lowered overall organic revenue growth by 0.5% to 1%.

IDEXX Laboratories: Fusion Of Innovation & Service Excellence In Veterinary Diagnostics! - Major Drivers

<ul><li>In 2023, IDEXX Laboratories posted strong quarterly and annual results.</li><li>The company reported an 8% organic revenue increase in Q4, largely driven by gains in CAG Diagnostic recurring revenues.</li><li>Operating profits also rose 8% as reported, with a 10% increase on a comparable basis, aided by robust gross margin gains and OpEx leverage.</li></ul>

In 2023, IDEXX Laboratories posted strong quarterly and annual results.The company reported an 8% organic revenue increase in Q4, largely driven by gains in CAG Diagnostic recurring revenues.Operating profits also rose 8% as reported, with a 10% increase on a comparable basis, aided by robust gross margin gains and OpEx leverage.

IDEXX Laboratories: Growing Global Direct Commercial Capability & Other Major Drivers

<ul><li>IDEXX Laboratories delivered a mixed result in the recent quarter, with revenues below market expectations, but it managed to surpass the analyst consensus in terms of earnings.</li><li>IDEXX experienced an impressive 8% organic growth in revenues, driven by a 9% surge in CAG Diagnostic recurring revenues.</li><li>Despite the headwinds from a decline in US clinical visits, IDEXX CAG Diagnostic recurring revenue growth remained resilient, surpassing sector growth levels.</li></ul>

IDEXX Laboratories delivered a mixed result in the recent quarter, with revenues below market expectations, but it managed to surpass the analyst consensus in terms of earnings.IDEXX experienced an impressive 8% organic growth in revenues, driven by a 9% surge in CAG Diagnostic recurring revenues.Despite the headwinds from a decline in US clinical visits, IDEXX CAG Diagnostic recurring revenue growth remained resilient, surpassing sector growth levels.

IDEXX Laboratories Inc.: Navigating Clinical Challenges – Key Growth Strategies! - Major Drivers

United States

IDEXX Laboratories, Inc. provides diagnostic, detection, and information systems for veterinary, food, and water testing applications. The Company also operates an international network of veterinary reference laboratories. IDEXX offers its products to customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

IDEXX Laboratories (IDXX US)

IDEXX Labs: Will Its Enhanced Diagnostic Capabilities & Innovation Bring A Shift In The Competitive Dynamics? - Major Drivers

IDEXX Laboratories, a prominent player in the diagnostics and veterinary healthcare sector, demonstrated a mixed performance in its latest...

Baptista Research

IDEXX Laboratories Inc.: Expanding Diagnostic Offerings & Executing Global Expansion & Strategic Acquisitions! - Major Drivers

IDEXX Laboratories recently reported its financial results for the second quarter of 2024. The company saw organic revenue growth of 7%, driven by...

Baptista Research

IDEXX Laboratories: Fusion Of Innovation & Service Excellence In Veterinary Diagnostics! - Major Drivers

IDEXX Laboratories began 2024 on a positive note, highlighted by strong profit gains and solid organic revenue growth. In the first quarter, the...

Baptista Research

IDEXX Laboratories: Growing Global Direct Commercial Capability & Other Major Drivers

In 2023, IDEXX Laboratories posted strong quarterly and annual results. The company reported an 8% organic revenue increase in Q4, largely driven...

Baptista Research

IDEXX Laboratories Inc.: Navigating Clinical Challenges – Key Growth Strategies! - Major Drivers

IDEXX Laboratories delivered a mixed result in the recent quarter, with revenues below market expectations, but it managed to surpass the analyst...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)